Accessibility

LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Potassium

CPT: 84132
Updated on 01/17/2020
Print Share

Expected Turnaround Time

Within 1 day


Related Documents


Specimen Requirements


Specimen

Serum (preferred) or plasma


Volume

1 mL


Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)


Container

Red-top tube, gel-barrier tube, or green-top (lithium heparin) tube

Red-top tube, gel-barrier tube, or green-top (heparin) tube

Red-top tube, gel-barrier tube, or green-top (lithium heparin) tube


Collection

Separate serum or plasma from cells within 45 minutes of collection; avoid hemolysis.


Storage Instructions

Maintain specimen at room temperature or refrigerate.


Stability Requirements

Temperature

Period

Room temperature

14 days

Refrigerated

14 days

Frozen

14 days

Freeze/thaw cycles

Stable x3


Causes for Rejection

Hemolysis; improper labeling; unspun or improperly spun specimen

Hemolysis; improper labeling; unspun or improperly spun specimen

Hemolysis; improper labeling; unspun or improperly spun specimen

Hemolysis; improper labeling; unspun or improperly spun specimen

Hemolysis; improper labeling; unspun or improperly spun specimen


Test Details


Use

Evaluate electrolyte balance; followed patients on diuretic therapy and with renal diseases, particularly salt-losing nephropathy; evaluate patients being treated for acidosis; prevent cardiac arrhythmias; evaluate alcoholism with delirium tremens; evaluate and treat ketoacidosis in diabetes mellitus; evaluate acid-base balance, water balance; manage intravenous therapy; evaluate anion gap; evaluate muscular weakness, leukemia, diseases of the gastrointestinal tract including laxative abuse, large villous adenomas, emesis, fistulas and tube drainage; detect, diagnose, and manage mineral corticoid excess (primary aldosteronism, Cushing syndrome, tumor with ectopic ACTH production, some cases of congenital adrenal hyperplasia); licorice ingestion. Potassium is increased in oliguria, anuria, urinary obstruction, renal failure due to shock (decreased removal of potassium), and renal tubular acidosis. Potassium is decreased in three ways:

• Inadequate intake

• Excessive loss due to diarrhea or vomiting or decreased reabsorption due to increased secretion of mineralocorticosteroids

• Movement into the cell as occurs with conditions causing alkalosis


Methodology

Ion-selective electrode (ISE)


Reference Interval

See table.

Age

Range (mmol/L)

0 to 7 d

3.7−5.2

8 to 30 d

3.7−6.4

1 to 6 m

3.8−6.0

7 m to 1 y

3.8−5.3

>1 y

3.5−5.2


Additional Information

Hypokalemia (low potassium) has been found in >90% of hypertensive patients with primary aldosteronism (Conn syndrome). This uncommon entity is a curable cause of hypertension. Low potassium occurs with endogenous or exogenous increase in other corticosteroids, including that in Cushing syndrome as well as with dietary or parenteral deprivation of potassium (eg, parenteral therapy without adequate potassium replacement). Hypokalemia occurs with vomiting, diarrhea, fistulas, laxatives, diuretics, burns, excessive perspiration, Bartter syndrome, some cases of alcoholism and folic acid deficiency, in alkalosis and in renal tubular acidosis as well as in other entities.

Low potassium is much more significant with a low pH than with a high pH. When pH increases by 0.1, potassium decreases approximately 0.6 mmol/L. With low pH, as in ketoacidosis, as therapeutic adjustment towards normal is made, plasma/serum K+ levels will decrease. Phosphorus levels tend to follow potassium levels downwards during therapy of diabetic ketoacidosis; both are largely intracellular. With insulin therapy (and increased utilization of carbohydrate), potassium moves into cells and serum/plasma level falls. Hyperalimentation may have a similar effect. Hypokalemia has been reported in slightly over one-half of a series of 32 patients with acute myelogenous leukemia,1 but thrombocytosis can increase serum potassium levels, vide supra.

Thiazide/chlorthalidone therapy may cause hyperuricemia and hypercalcemia as well as hypokalemia.

The watery diarrhea-hypokalemia-achlorhydria (WDHA) syndrome most often is related to vasoactive intestinal polypeptide (VIP).

Hyperkalemia (high potassium) reflects generally inadequate renal excretion, mobilization of potassium from the tissues, or excessive intake or administration. Hyperkalemia occurs with hemolysis, trauma, with administration of potassium salts of some drugs, Addison disease, acidosis, insulin lack, with increased osmolality (eg, glucose, mannitol), and in other entities as well as with renal diseases. Increased potassium can occur with potassium sparing diuretics, nonsteroidal anti-inflammatory drugs, especially in the presence of renal disease. Systemic heparin therapy can suppress aldosterone release and increase potassium, especially in the presence of other factors.

A discussion of the relation between lactic acidosis and ketoacidosis and elevated serum potassium levels is provided in a paper by Fulop.2

Drug effects are summarized.3


Footnotes

1. Mir MA, Brabin B, Tang OT, Leyland MJ, Delamore IW. Hypokalaemia in acute myeloid leukaemia. Ann Intern Med. 1975; 82(1):54-57. 16553
2. Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med. 1979 May 10; 300(19):1087-1089 (review). 34793
3. Hitz J, Trivin F. Potassium. In: Siest G, Galteau MM, eds.Drug Effects on Laboratory Test Results Analytical Interferences and Pharmacological Effects. Littleton, Mass: PSG Publishing Co Inc;1988: 362-374.

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
001180 Potassium 2823-3 001180 Potassium mmol/L 2823-3

For Providers

Please login to order a test

Order a Test

© 2019 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf